CardioKinetix said its Parachute ventricular partitioning device was used to treat 2 patients in Beijing.
The Parachute device is used to restore damage to the left ventricle after a heart attack by partitioning the space to its usual geometry and function, according to a press release.
Last month, Menlo Park, Calif.-based CardioKinetix announced the 1st use of the Parachute device in Asia, after it was used to treat a patient in Malaysia. The device won CE Mark approval in the European Union and is undergoing a pivotal trial in the U.S. under an investigational device exemption from the FDA.
“These initial cases in China mark another key milestone in CardioKinetix’s journey to bring Parachute to heart failure patients around the world. China represents a key strategic opportunity for the company as we further our international expansion,” CardioKinetix president & CEO Maria Sainz said in prepared remarks.